“癌症之王”胰腺癌新疗法！疾病控制率达100%！
1月28日，ImmunoMet Therapeutics公布其在研小分子Lixumistat联合吉西他滨（Gemcitabine）和白蛋白结合型紫杉醇（Nab-paclitaxel），作为一线疗法治疗晚期胰腺癌患者的结果。 胰腺癌因发病隐匿，恶性程度极高，预后效果极差，被称为“癌症之王”。近年来，针对胰腺癌的创新疗法不断增多，为胰腺癌治疗提供了新的选择。 近期，在研小分子Lixumistat联合吉 ...
Study finds cryotherapy treatment is effective in reducing neuropathy in breast cancer patients
A new study led by a George Washington University Cancer Center researcher found that cold therapy protects breast cancer ...
Cure Today5 天
GAP Triplet May Be Less Safe Than Doublet Chemo in Biliary Tract Cancer
An expert explains that the GAP regimen did not improve overall survival in advanced biliary tract cancer versus the doublet ...
Cancer Therapy Advisor18 天
Ibrilatazar Plus Chemo Deemed Promising for Squamous NSCLC
Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...
Knowridge7 天
Cold therapy can reduce nerve pain in breast cancer patients
A new study led by researchers at the George Washington University Cancer Center has found that cold therapy, also known as ...
Cure Today13 天
GAP Regimen May Not Improve Survival in Biliary Tract Cancer Subset
The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.
precisionmedicineonline10 天
Perthera AI-Driven Predictor Enables Molecularly Guided Therapy for First-Line Pancreatic ...
The tool predicts which of two standard front-line chemotherapy options a patient with advanced pancreatic cancer is likely to benefit from.